These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 30453288

  • 1. Predictive Early Recurrence Factors of Preoperative Clinicophysiological Findings in Pancreatic Cancer.
    Suzuki S, Shimoda M, Shimazaki J, Maruyama T, Oshiro Y, Nishida K, Sahara Y, Nagakawa Y, Tsuchida A.
    Eur Surg Res; 2018; 59(5-6):329-338. PubMed ID: 30453288
    [Abstract] [Full Text] [Related]

  • 2. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M, Pilarsky E, Kersting S, Grützmann R.
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [Abstract] [Full Text] [Related]

  • 3. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
    Chen T, Zhang MG, Yu XJ, Liu L.
    Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
    [Abstract] [Full Text] [Related]

  • 4. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
    Kim J, Lee YS, Hwang IK, Kang BK, Cho JY, Yoon YS, Han HS, Hwang JH.
    J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
    [Abstract] [Full Text] [Related]

  • 5. Serum SPan-1 Is a Significant Risk Factor for Early Recurrence of Pancreatic Cancer after Curative Resection.
    Hosokawa Y, Nagakawa Y, Sahara Y, Takishita C, Katsumata K, Tsuchida A.
    Dig Surg; 2017 Mar; 34(2):125-132. PubMed ID: 27658221
    [Abstract] [Full Text] [Related]

  • 6. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
    Xu HX, Liu L, Xiang JF, Wang WQ, Qi ZH, Wu CT, Liu C, Long J, Xu J, Ni QX, Yu XJ.
    Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
    [Abstract] [Full Text] [Related]

  • 7. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
    Rieser CJ, Zenati M, Hamad A, Al Abbas AI, Bahary N, Zureikat AH, Zeh HJ, Hogg ME.
    Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
    [Abstract] [Full Text] [Related]

  • 8. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
    Dong Q, Yang XH, Zhang Y, Jing W, Zheng LQ, Liu YP, Qu XJ.
    World J Surg Oncol; 2014 Jun 02; 12():171. PubMed ID: 24890327
    [Abstract] [Full Text] [Related]

  • 9. Prognostic impact of carcinoembryonic antigen and carbohydrate antigen 19-9 in stage IV colorectal cancer patients after R0 resection.
    Abe S, Kawai K, Ishihara S, Nozawa H, Hata K, Kiyomatsu T, Tanaka T, Watanabe T.
    J Surg Res; 2016 Oct 02; 205(2):384-392. PubMed ID: 27664887
    [Abstract] [Full Text] [Related]

  • 10. Serum Marker Score Based on Prognostic Nutrition Index, Carcinoembryonic Antigen, and Carbohydrate Antigen 19-9 Is Associated With Recurrence for Patients Undergoing Surgery for Pancreatic Ductal Adenocarcinoma.
    Nakagawa S, Yamashita YI, Umezaki N, Yamao T, Okabe H, Imai K, Nitta H, Hashimoto D, Chikamoto A, Baba H.
    Pancreas; 2018 Oct 02; 47(9):1130-1134. PubMed ID: 30161074
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis.
    Kim JK, DePeralta DK, Ogami T, Denbo JW, Pimiento J, Hodul PJ, Malafa MP, Kim DW, Fleming JB, Powers BD.
    J Surg Oncol; 2020 Nov 02; 122(6):1074-1083. PubMed ID: 32673436
    [Abstract] [Full Text] [Related]

  • 15. Serum tumor markers not useful in screening patients with pancreatic mucinous cystic lesions associated with malignant changes.
    Pezzilli R, Calculli L, Melzi d'Eril G, Barassi A.
    Hepatobiliary Pancreat Dis Int; 2016 Oct 02; 15(5):553-557. PubMed ID: 27733327
    [Abstract] [Full Text] [Related]

  • 16. ABO blood type, smoking status, other risk factors and prognosis of pancreatic ductal adenocarcinoma.
    Li SS, Zhou CY, Liao R, Xiong L, Weng NN, Zhao YQ, Mason C, Gou HF, Yi C, Zhu Q.
    Medicine (Baltimore); 2020 Apr 02; 99(14):e19413. PubMed ID: 32243360
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma.
    Izumo W, Higuchi R, Furukawa T, Yazawa T, Uemura S, Shiihara M, Yamamoto M.
    Scand J Gastroenterol; 2019 Jun 02; 54(6):780-786. PubMed ID: 31180790
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
    Chung HW, Lim JB, Jang S, Lee KJ, Park KH, Song SY.
    Cancer Sci; 2012 Sep 02; 103(9):1714-21. PubMed ID: 22703527
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.